# Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Source: https://onco.cc/trials/nct06895031/  
OnCo record `nct06895031` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of JYP0015 in pancreatic ductal adenocarcinoma and non-small-cell lung cancer, run by Guangzhou JOYO Pharma Co., Ltd, now recruiting.

## Summary

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS is a phase 2 interventional study registered as NCT06895031 by Guangzhou JOYO Pharma Co., Ltd, with 210 participants planned, started 2025-03-31 and due to reach its primary completion in 2026-03-30. Interventions recorded: JYP0015. Conditions listed: Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06895031
- Phase: 2
- Setting: A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation
- Sponsor: Guangzhou JOYO Pharma Co., Ltd
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT06895031: https://clinicaltrials.gov/study/NCT06895031

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [JYP0015](https://onco.cc/drugs/jyp0015/)

---
JSON: https://onco.cc/api/v1/entities/nct06895031.json